Replies to post #234305 on Cytodyn Inc (CYDY)

[Monroe1]

LOL, spilled my coffee reading your post.
What planet are you posting from now?
Feeling the pinch???? Get used to it like for the past number of months... up up and away.
$$$$CYDY$$$$ 2025 and BEYOND

“As a cancer therapeutic, leronlimab was well tolerated with remarkably infrequent treatment-related adverse events. These promising results suggest further studies with leronlimab are warranted to expand oncology treatment options and improve patient care.” Pestell

CytoDyn ( CYDY ) worked with consultants and key opinion leaders to summarize the findings and submit an abstract to the European Society for Medical Oncology (ESMO) Breast Cancer meeting taking place in Munich, Germany, from May 14 to 17, 2025. Boom da boom as they say.

Dr. Jacob Lalezari, CEO of CytoDyn ( CYDY ), added: "........
I expect the Company’s oncology efforts to accelerate in the coming months, with further announcements in both mTNBC and colorectal cancer.”